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http://dx.doi.org/10.1016/j.ccell.2015.02.014SUMMARYMany cancers harbor oncogenic mutations of KRAS. Effectors mediating cancer progression, invasion, and
metastasis in KRAS-mutated cancers are only incompletely understood. Here we identify cancer cell-ex-
pressed murine TRAIL-R, whose main function ascribed so far has been the induction of apoptosis as a
crucial mediator of KRAS-driven cancer progression, invasion, and metastasis and in vivo Rac-1 activation.
Cancer cell-restricted genetic ablation of murine TRAIL-R in autochthonous KRAS-driven models of non-
small-cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) reduces tumor growth, blunts
metastasis, and prolongs survival by inhibiting cancer cell-autonomous migration, proliferation, and inva-
sion. Consistent with this, high TRAIL-R2 expression correlates with invasion of human PDAC into lymph ves-
sels and with shortened metastasis-free survival of KRAS-mutated colorectal cancer patients.Significance
Previous preclinical and clinical studies have explored the pro
cancer drugs exploiting the fact thatmany cancers highly expre
TRAIL-R expression is still unknown. Here, we identify cancer
sion, invasion, and metastasis in KRAS-mutated cancers, sugg
system is positively selected for in these cancers. Important
blockade. Therefore, inhibiting, rather than triggering, human
for patients with KRAS-mutated cancers.-apoptotic function of TRAIL and TRAIL-R agonists as anti-
ss TRAIL-Rs. However, the cancer biological function of high
cell endogenous TRAIL-R signaling to drive cancer progres-
esting that this nonapoptotic function of the TRAIL/TRAIL-R
ly, this receptor/ligand system is amenable to therapeutic
TRAIL-R2 should be explored as a therapeutic approach
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INTRODUCTION
Twenty-one percent of all human cancers bear oncogenic muta-
tions in KRAS (Bos, 1989), and their frequency is highest in some
of the most aggressive cancers, such as 95% of pancreatic
ductal adenocarcinoma (PDAC) (Hidalgo, 2010; Jaffee et al.,
2002), 50% of colorectal adenocarcinoma (Grady and Marko-
witz, 2002), and 30% of non-small-cell lung cancers (NSCLCs)
(Mitsuuchi and Testa, 2002). Whereas direct therapeutic target-
ing of mutated KRASG12C has recently been achieved (Ostrem
et al., 2013), cancers driven by all other forms of oncogenic
KRAS remain difficult to treat. Many effector pathways down-
stream of KRAS have been implicated in KRAS-driven tumor
development and maintenance (Castellano et al., 2013; Down-
ward, 2008; Engelman et al., 2008; Gupta et al., 2007; Ling
et al., 2012). Therefore, small molecule inhibitors targeting these
pathways have been developed (Baines et al., 2011). Their
recent clinical application has, however, highlighted that many
of these inhibitors activate resistance-causing feedback mecha-
nisms and give cause for concern over toxicity in the clinic.
TNF-related apoptosis-inducing ligand (TRAIL, also known as
Apo2L) can selectively kill tumor cells in vivo (Ashkenazi et al.,
1999; Walczak et al., 1999). These findings have initiated the
development of TRAIL and other TRAIL-receptor (TRAIL-R) ago-
nists for cancer therapy (reviewed in Lemke et al., 2014). Many
tumor cell lines and primary tumors are, however, resistant to
TRAIL-induced apoptosis (Koschny et al., 2007; Todaro et al.,
2008). In addition, TRAIL also has been shown to activate nona-
poptotic signaling pathways in cancer cell lines such as nuclear
factor-kB (NF-kB) (Degli-Esposti et al., 1997; Ehrhardt et al.,
2003; Harper et al., 2001; Ishimura et al., 2006; Varfolomeev
et al., 2005), the mitogen-activated kinases (MAPKs) JNK, p38
(Varfolomeev et al., 2005), and ERK (Belyanskaya et al., 2008),
as well as the kinase Src (Azijli et al., 2012). These adverse ef-
fects were confirmed to be relevant in vivo as therapeutic TRAIL
administration promoted liver metastasis of xenotransplanted
PDAC (Trauzold et al., 2006) and KRAS-mutated colorectal can-
cer (CRC) cell lines (Hoogwater et al., 2010).
Whereas these findings have highlighted potential adverse ef-
fects of TRAIL as a single agent therapy, the basic biological
question as to why cancer cells would retain TRAIL-R expression
if they were resistant to apoptosis induction by TRAIL remained
unresolved.
We hypothesized that the endogenous TRAIL/TRAIL-R sys-
tem might play a role in promoting apoptosis-resistant cancers,
which could provide an explanation for the seemingly counterin-
tuitive high expression of TRAIL-Rs and TRAIL in many types of
cancer (Elrod et al., 2010; Ganten et al., 2009; Macher-Goep-
pinger et al., 2009; Ozawa et al., 2001; Sanlioglu et al., 2007),Figure 1. KRAS-Driven Lung and Pancreatic Cancers Are Promoted vi
(A) Images of representative lungs of the indicated 6-month-old KP mice.
(B) Lungs from (A) were weighed, and their weight was plotted in comparison to
(C) Kaplan-Meier survival curve of mice with indicated genotypes. Statistics wer
(D) Images of representative pancreata of the indicated 4.5-month-old KC mice.
(E) Fixed pancreata were stained with H&E, and the number of PanINs per pancre
top of the box are the 25th and 75th percentile of the data, respectively. The whisk
bar represents 100 mm.
(F) Representative H&E, aCK19 and DAPI stainings of pancreas of mice of indicaincluding NSCLC in which high TRAIL-R2 expression positively
correlated with increased risk of death (Spierings et al., 2003).
Therefore, we set out to interrogate the role of cancer cell-ex-
pressed TRAIL-Rs in KRAS-driven cancer.
RESULTS
Cancer Cell-Expressed mTRAIL-R Promotes
Autochthonous KRAS-Driven Lung Cancer and
Formation of Pancreatic Intraepithelial Neoplasia
We started our investigation using a variant of the KP murine
NSCLC model (Jackson et al., 2001) in which oncogenic
KRASG12D and p53R172H are expressed from their respective
endogenous loci upon adenoviral-Cre (Ad-Cre) infection to give
rise to lung tumors that closely resemble humanNSCLC (Kasinski
and Slack, 2012). Unlike humans, mice express only one death-
domain (DD)-containing TRAIL-R, mTRAIL-R (MK/mDR5), which
is homologous to both human TRAIL-R1 and TRAIL-R2 (Wu et al.,
1999). To interrogate the role ofmTRAIL-R inNSCLC,wecrossed
conditional mTRAIL-R knockout (KO) mice (Grosse-Wilde et al.,
2008) with KPmice and induced lung tumors byAd-Cre infection.
Genetic ablation of mTRAIL-R in cancer cells substantially
reduced lung tumor size (Figure 1A) and weight (Figure 1B) in
age-matched groups (mTRAIL-R deletion within the largest
tumor nodule per lung was confirmed; data not shown). Impor-
tantly, reduced lung tumor burden in mTRAIL-R-ablated lungs
translated into significantly prolonged survival after tumor initia-
tion (Figure 1C).
Although the incidence of KRAS mutations is relatively high
among NSCLC (30%), it is even higher in PDAC (95%) (Hidalgo,
2010; Jaffee et al., 2002), which also overexpresses TRAIL-Rs
(Ozawa et al., 2001). Thus, we next determined the role of
mTRAIL-R in the initiation of pancreatic cancer. To this end, we
made use of KrasG12D;PDX-1-Cre (KC) mice, in which oncogenic
KRASG12D expression is initiated viaCre-recombinase expressed
from the PDX-1 promoter leading to mosaic expression of Cre-
recombinase and the development of pancreatic intraepithelial
neoplasia (PanIN) (Hingorani et al., 2003). Pancreata of age-
matched KC mice crossed to conditional mTRAIL-R KO mice
were macroscopically normal, albeit slightly smaller than KC-
mTRAIL-R WT pancreata (Figure 1D). Importantly, cancer cell-
specific absence of mTRAIL-R markedly reduced the number of
PanINs that developed in these mice (KC-mTRAIL-RFL/FL) as
compared with littermate controls (KC-mTRAIL-RWT/WT) (Fig-
ure 1E). The presence of PanINs was confirmed by inspecting
sections stained for the epithelial marker CK19, commonly used
to distinguish PanINs from normal tissue (Figure 1F). Together,
these results demonstrate that cancer cell-expressed mTRAIL-R
promotes KRAS-driven NSCLC and PanIN formation.a Endogenous mTRAIL-R
age-matched C57BL/6 mice.
e determined by log-rank test, ***p = 0.0008.
atic section was determined by histopathological examination. The bottom and
ers represent maximum and minimum values, *p < 0.05 (Student’s t test). Scale
ted genotypes. Scale bar represents 25 mm.
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Figure 2. Human TRAIL-R2 Drives Proliferation, Migration, and Invasion
(A) A549 shControl, shTRAIL-R1, and shTRAIL-R2 were subjected to soft agar colony formation assays. Relative colony formation was determined normalized to
A549-luc pLKO.1 after 4 weeks.
(B) KRAS-mutated Panc Tu I, A549-luc and DLD-1 cells were subjected to control or TRAIL-R2 KD for 72 hr and then BrdU proliferation assays.
(C) Six KRAS-mutated and five KRAS-WT cell lines were transfected with siRNAs silencing TRAIL-R2 or mTRAIL-R and subsequently subjected to migration
assays. Migration was normalized to control transfected cells in each of the cell lines.
(D) KRAS-mutated cells as in (C) apart from H460 and KRAS-WT cells as in (C) were transfected with siRNAs silencing human or murine KRAS and subjected to
migration assays.
(E) DLD-1 and DKO4 cells were transfected as indicated and subjected to migration assays. Migration was normalized to control transfected DKO4 cells.
(F) Panc Tu I cells were transfected as indicated and subjected to migration assays.
(G) A549-luc, DLD-1, and Colo357 cells were subjected to invasion assays.
(legend continued on next page)
564 Cancer Cell 27, 561–573, April 13, 2015 ª2015 Elsevier Inc.
Human TRAIL-R2 Drives Cancer Cell Proliferation,
Migration, and Invasiveness
Humans express two mTRAIL-R homologs, TRAIL-R1 and
TRAIL-R2. Therefore, we next tested whether and which of
these two receptors could be responsible for the promotion of
oncogenic cellular traits. Interestingly, stable RNA interference
(RNAi)-mediated suppression of TRAIL-R2, but not TRAIL-R1,
in the KRAS-mutated NSCLC cell line A549 led to reduced col-
ony formation in soft agar (Figure 2A). In addition, knockdown
(KD) of TRAIL-R2 in KRAS-mutated Panc Tu I (pancreas), A549
(lung), and DLD-1 (colon) cells, representing the three most
common cancer types with KRAS mutations led to decreased
proliferation in two of three cell lines (Figure 2B). Irrespective of
this mixed response between cell lines, KD of TRAIL-R2 or
mTRAIL-R reduced basal migration of KRAS-mutated cell lines
further than that of KRAS-WT cells, irrespective of tissue origin
(Figures 2C, S1A, and S1B; Table S1). Despite detectable
expression of both DD-containing TRAIL-Rs (Figure S1C), migra-
tion was affected only by KD of TRAIL-R2 (Figure S1D).
Intriguingly, the suppressive effect of KD of TRAIL-R2 on
migration was almost identical to that of KD of KRAS (Figure 2D).
To test whether TRAIL-R2-mediated migration would be respon-
sible for the increased migratory capacity observed in KRAS-
mutated as compared with KRAS-WT cells, we used isogenic
colon carcinoma cell lines that contained the oncogenic mutant
KRAS (KRASG13D) and WT allele (DLD-1) or only the WT allele
(DKO4) (Shirasawa et al., 1993). KD of TRAIL-R2 abrogated the
enhanced migratory capacity of KRAS-mutated DLD-1 cells,
whereas basal migration of KRAS-WT DKO4 cells remained un-
altered (Figure 2E) despite expression of comparable levels of
TRAIL-R2 and efficient KD (Figure S1E). Moreover, TRAIL-R2-
mediated migration was ligand dependent as KD of endogenous
TRAIL reduced migration to a similar extent as TRAIL-R2 KD
alone or the combined KD of both proteins (Figure 2F). In addi-
tion, TRAIL blockage using TRAIL-R2-Fc similarly inhibited
migration (Figure S1F). Interestingly, when subjecting native
cell lysates to size-exclusion chromatography (SEC), a portion
of TRAIL-R2 was present in high molecular weight fractions
along with endogenous TRAIL (Figure S1G). Furthermore, KD
of TRAIL led to a shift of TRAIL-R2 from high molecular weight
fractions to the size range of trimerized TRAIL-R2 (Figure S1H).
Besides affecting migration, TRAIL-R2-KD also blunted invasion
to nearly the same low level exhibited by the noninvasive cell line
NIH 3T3 (Figure 2G).
Finally, absence of human TRAIL-R2 or systemic inhibition of
TRAIL using TRAIL-R2-Fc treatment also suppressed lung tumor
growth (Figures 2H, S1I, and S1J) and PDAC liver metastasis in a
previously described PDAC metastasis model (Figures 2I and(H) 2 3 106 A549-luc pLKO.1 or shTRAIL-R2 were injected intravenously into SC
sections of H&E-stained lungs by pathological inspection.
(I) 1 3 106 PancTu-I shCtr (n = 9) or shTRAIL-R2 (n = 8) were orthotopically impl
resected, and the number of liver macrometastases was determined.
(J) A schematic representation of TRAIL-R2 mutants.
(K) A549 shTRAIL-R2 cells were transiently transfected with either vector (pcDN
migration assays. Migration was normalized to A549-luc pLKO.1 cells.
Representative western blots are shown. Figures represent means of three ind
surements from a single cell line shown as amean of three independent experimen
ICD, intracellular domain; CTD, C-terminal domain. ns, not significant, *p < 0.05, **
Whitney test, I).
See also Figure S1 and Table S1.S1K) (Egberts et al., 2008). Thus, TRAIL-R2 is the human
homolog of mTRAIL-R responsible for stimulating tumor growth,
migration, and metastasis.
TRAIL triggers apoptosis through formation of the death-
inducing signaling complex (DISC) containing FADD, caspase-8
and caspase-10 and cFLIP (Kischkel et al., 2000, 2001; Sprick
et al., 2000, 2002). Surprisingly, we found that suppression of
caspase-8 did not affect migration (Figure S1L), and TRAIL-R2
KD still inhibited migration of three independent A549 FADD KO
clones (Figure S1M). TRAIL-R2-mediated migration therefore
does not require the DISC.
To identify the intracellular migration effector domain of
TRAIL-R2, we next reconstituted stable TRAIL-R2 KD cells
with either full-length TRAIL-R2 or mutants lacking the entire
intracellular domain (DICD), the DD (DDD), the short C-terminal
domain (DCTD), or the DD and CTD (DDD/CTD) (Figure 2J).
Expression of the full-length TRAIL-R2, DDD/CTD, or DCTD
was sufficient to reconstitute migration (Figure 2K). Therefore,
the membrane-proximal domain (MPD) of TRAIL-R2, a domain
with previously unknown function, is the minimum intracellular
domain required to reconstitute migration.
Spontaneous Metastasis in KRAS-Driven PDAC
Requires Cancer Cell-Expressed mTRAIL-R
Since human TRAIL-R2 was required for migration and invasion
besides proliferation (Figure 2), we next investigated the role of
mTRAIL-R in themetastatic KPCmousemodel of PDAC (Hingor-
ani et al., 2005). Recombination of the floxed mTRAIL-R allele
could be detected in the pancreata of KPC-mTRAIL-RFL/FL
mice along with remaining floxed alleles due to mosaic expres-
sion of Cre (Figure S2A). Absence of mTRAIL-R from KPC
pancreatic cancer cells increased survival from a median of
112 days in KPC-mTRAIL-RWT/WT mice to 180 days in KPC-
mTRAIL-RFL/FL mice (Figure 3A). As primary tumor size is known
to be the main determinant of endpoint in this model, mTRAIL-
RFL/FL KPC tumors must have taken longer to reach the same
size as WT tumors in order to result in prolonged survival in the
absence of mTRAIL-R. Moreover, both groups had equally sized
primary tumors at their respective times-of-death (Figure S2B)
despite the fact that there was considerably more time for tu-
mors to grow in the mTRAIL-RFL/FL group. These results, in
conjunctionwith the results obtained in the KCmodel (Figure 1E),
imply that delayed primary tumor growth is a consequence of de-
layed PanIN formation and that this is responsible for increased
survival of KPC mice with conditional mTRAIL-R deletion.
When examining animals for presence of distant metastases,
we detected liver and lung metastases in a high percentage
of KPC-mTRAIL-RWT/WT mice while liver metastases wereID beige mice (n = 9 mice per group). Tumor burden was quantified in paraffin
anted into pancreata of SCID beige mice. After 10 days, primary tumors were
A3.1) or with the indicated TRAIL-R2 version and subsequently subjected to
ependent experiments ± SEM; individual dots represent the results of mea-
ts or sample from a singlemousewhen applicable. Ctr, control; TR2, TRAIL-R2;
p < 0.01, and ***p < 0.001 (ANOVA: A, B, E–G, K; Student’s t test: C, D, H; Mann-
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Figure 3. mTRAIL-R Promotes KRAS-Driven Pancreatic Cancer Progression and Metastasis
(A) Kaplan-Meier survival curve, log-rank test, **p = 0.004.
(B) Animals with metastasis in the liver and lungs as determined by H&E staining at time of death were quantified. Three of KPC-TRAIL-RWT/WT could not be
determined due to tissue decay. Fisher’s exact test ***p > 0.001 and *p > 0.05.
(C) Representative H&E stainings of pancreatic adenocarcinomas and lung tissues. Met, metastasis. Scale bar represents 50 mm.
(D) Representative images of isotype, aPDX-1, aSp-C, and aCC10 stainings of KPC lung metastases. Scale bar represents 25 mm.
(E) Representative images of aCC10 stainings of KP lung tumors. Scale bar represents 25 mm.
See also Figure S2.completely absent and lung metastases present in only two out
of eleven mTRAIL-RFL/FL KPC mice (Figures 3B and 3C).
To confirm that lung lesions in KPC mice originated from the
pancreas, we stained for PDX1, a weakly expressed but specific
pancreatic marker, Sp-C, a marker for alveolar type II epithelial
cells, and CC10, a specific marker for Clara cells because
KRAS-driven lung tumors in mice have previously been shown
to be Sp-C positive and CC10 negative (Sotillo et al., 2010).
KPC lung lesions stained positive for PDX1 and negative for
Sp-C and CC10 and were therefore of pancreatic origin (Fig-
ure 3D), whereas comparative stainings of primary murine lung
cancers from KP mice were positive for Sp-C and negative for
CC10 within tumors (Figure 3E). Of note, the overall occurrence
of metastasis did not correlate with primary tumor size (Fig-
ure S2C). Together, this demonstrates that failure to efficiently
metastasize in the absence of mTRAIL-R is not a consequence
of delayed primary tumor formation but specifically disabled by
absence of mTRAIL-R from KRAS-driven pancreatic cancer.
Thus, mTRAIL-R deletion in KRAS-driven PDAC delays primary
tumor growth, prolongs survival, and blunts metastasis.566 Cancer Cell 27, 561–573, April 13, 2015 ª2015 Elsevier Inc.Cell-Autonomous TRAIL-R2 Stimulation Promotes
Activation of Promigratory Rac1/PI3K Signaling
We noted that TRAIL-R2-KD cells had a more rounded
morphology than control cells and lacked lamellipodia (Fig-
ure 4A). Interestingly, the same morphology was described for
cells deficient in the small GTPase Rac1 (Steffen et al., 2013),
an important mediator of migration and invasion (Sanz-Moreno
and Marshall, 2010). When testing whether this pathway was
affected, we found that Rac1 activity was substantially reduced
by TRAIL-R2 KD (Figure 4B). Moreover, silencing of Rac1
reduced migration to a similar extent as TRAIL-R2 KD, and no
additional reduction was achieved by co-suppression of
TRAIL-R2 and Rac1, suggesting that TRAIL-R2 and Rac1 might
act sequentially in one pathway (Figure 4C). Further substantiat-
ing this notion, while suppression of the small GTPase RhoA,
known to negatively regulate Rac1 activity via ROCK activation
(Sanz-Moreno et al., 2008), significantly increased migration,
thiswas completely reversedbyco-KDof TRAIL-R2 (FigureS3A).
Intriguingly, overexpressed Rac1 but not dominant negative (dn)
Rac1 bound to TRAIL-R2 (Figure 4D) and GTP-bound but not
GDP-bound Rac1 formed part of a complex with TRAIL-R2 and
TRAIL (Figure 4E). Rac1 is known to be able to promote both
migration and proliferation/tumor growth (Heasman and Ridley,
2008; Myant et al., 2013). In line with this, pharmacological
Rac1 inhibition strongly impaired proliferation only in cell lines
in which TRAIL-R2 promoted proliferation (Figure 4F).
Rac1 activation has been described to be either dependent or
independent of phosphoinositide 3-kinase (PI3K) (Lambert et al.,
2002; Nimnual et al., 1998). Therefore, we first interrogated
whether KD of PTEN, which counteracts PI3K activity (Ali et al.,
1999), would stimulate PI3K-dependent migration. Indeed, sup-
pression of PTEN strongly induced migration, all of which could
be blocked by treatment with the PI3K inhibitor GDC-0941 (Fig-
ure 4G). Furthermore, KD of TRAIL-R2 reduced phosphorylation
of AKT in both presence and absence of FADD and was induced
by expression of TRAIL-R2 DDD/CTD but not by DICD (Fig-
ure 4H). KRAS requires direct p110a subunit binding to activate
PI3K (Gupta et al., 2007). In order to test whether oncogenic
KRAS required TRAIL-R2 for this, we subjected a KRAS-WT
cell line with inducible KRASG13D expression (Figure S3B) to
TRAIL-R2 or control KD and treatment with either the p110a-
(A66) or p110b-specific inhibitor (TGX221). TRAIL-R2-KD did
not affect KRAS-mediated pAKT induction that was p110a
dependent (Figure S3C). PI3K-dependent migration instead
required p110b activity (Figure S3D). Interestingly, a recent study
demonstrated that GTP-bound Rac1 interacts with p110b
(Fritsch et al., 2013), which was also the case in cells using
TRAIL-R2 for migration (Figure S3E). Importantly, PI3K-depen-
dent migration and increased phosphorylation of AKT could be
reversed by co-suppression of either TRAIL-R2 or Rac1 (Fig-
ure 4I). Together, these results place TRAIL-R2 upstream of
Rac1 and Rac1 upstream of PI3K activity in the cell migration
pathway triggered by endogenous TRAIL/TRAIL-R2.
The question remained, however, how oncogenic KRAS al-
lowed for TRAIL-R2-mediated migration. Interestingly, KRAS-
mutated cells are resistant to TRAIL-induced apoptosis through
KRAS-mediated ROCK suppression (Hoogwater et al., 2010).
Moreover, Rac1-mediated mesenchymal migration is inhibited
by ROCK (Sanz-Moreno et al., 2008). Based on these findings,
we interrogatedwhether pharmacological ROCK inhibitionmight
be sufficient to release a constraint on Rac1 activation in KRAS-
WT cells and thus enable TRAIL-R2-mediated migration. KRAS-
mutated cells showed constitutive suppression of ROCK activity
as compared with isogenic WT cells (Hoogwater et al., 2010)
(Figure S3F). Pharmacological ROCK inhibition using the inhibi-
tor Y27632 was indeed sufficient to induce TRAIL-R2-mediated
migration in KRAS-WT cells (Figure S3G). Moreover, this same
ROCK-inhibitor-induced migration that was dependent on
TRAIL-R2 could be reversed by PI3K inhibition (Figure S3H)
demonstrating that ROCK inhibition, mediated by oncogenic
KRAS, removes a constraint on TRAIL-R2-mediated migration.
Thus, we propose a model in which endogenous TRAIL/TRAIL-
R2 promote a Rac1/PI3K signaling axis in KRAS-mutated cells,
which in turn drives proliferation and migration (Figure 4J).
mTRAIL-R Activates Rac1 in KPC-Derived Tumors
In Vivo
Fo¨rster resonance energy transfer (FRET) is a highly sensitive
method that has been used widely to determine RhoGTPase ac-tivity in real time (Aoki and Matsuda, 2009; Hodgson et al., 2010;
Kraynov et al., 2000). In order to monitor Rac1 activity, the ‘‘Rai-
chu’’ (Ras superfamily and interacting protein chimeric unit) Rac-
FRET probe has been developed in which Rac1 coupled to a
fluorescent protein is fused to the fluorophor-coupled CRIB
domain of the RacGTP-binding protein Pak1 (Itoh et al., 2002)
(Figure S4A). To test whether mTRAIL-R would affect Raichu-
Rac activity, we generated stable mTRAIL-R KD lines using
two different shRNA sequences (23 and 25) from previously
generated KPC-derived cell lines (Morton et al., 2010). These
cells were subsequently transfected with a Rac-FRET probe
suitable for intravital imaging and transplanted into Nude mice
(Figure S4B). Subsequently, in vivo Rac1 activity was determined
by intravital microscopy using cutaneous optical imaging win-
dows (Ritsma et al., 2013). Strikingly, absence of mTRAIL-R
fromKPC subcutaneous tumors resulted in a significant increase
in average fluorescent lifetime, corresponding to decreased
Rac1 activity in both stable KD clones in live KPC tumors in vivo
(Figures 5A and 5B). Moreover, blocking mTRAIL by systemic
treatment withmTRAIL-R-Fc also strongly inhibited Rac1 activity
in subcutaneous KPC tumors, providing evidence for endoge-
nous TRAIL as stimulus for mTRAIL-R-mediated Rac1 activation
in vivo (Figure 5C). Since systemic blockade of TRAIL can equally
block host and cancer cell-derived TRAIL, we tested whether
KPC-derived Rac-FRET cells were in principle self-sufficient in
producing TRAIL to stimulate mTRAIL-R in vitro. Indeed,
in vitro treatment of KPC-Rac-FRET cells with mTRAIL-R-Fc
was sufficient to inhibit Rac1 activity (Figure 5D). Together, these
data show thatKRAS-mutated KPC-derived tumors use the can-
cer cell-expressed mTRAIL/mTRAIL-R system to promote Rac1
activity in vivo.
High TRAIL-R2 Expression Correlates with Parameters
of Malignancy in Patients with KRAS-Mutated Cancers
To evaluate the relevance of TRAIL-R2 in human cancers with
KRAS mutations, we analyzed TRAIL-R1 and TRAIL-R2 expres-
sion in primary PDAC resected from patients. In a cohort of 95
tumors, 84% of PDAC highly expressed TRAIL-R2, whereas
expression of TRAIL-R1 was high in only 9% of PDAC with all
other tumors being either negative or low for TRAIL-R1 expres-
sion (Figure 6A). Of note, it was previously shown that only
TRAIL-R1 is used for apoptosis induction in PDAC cell lines
(Lemke et al., 2010), suggesting that human PDAC might select
for expression of TRAIL-R2 and against that of TRAIL-R1. Impor-
tantly, when analyzing another PDAC cohort (n = 106) with addi-
tional clinical information, high TRAIL-R2 expression correlated
with lymph vessel invasion of tumors (Figure 6B).
Metastases from PDAC patients are rarely resected and thus
seldom available for histological analysis. We therefore analyzed
TRAIL-R1 and TRAIL-R2 expression in lung metastases of a
cohort of 36 CRC patients of which 18 carried oncogenic
KRAS mutations and 18 were KRAS-WT. In contrast to the
PDAC cohorts, TRAIL-R1 and TRAIL-R2 were both expressed
at detectable levels in lung metastases of KRAS-mutated and
KRAS-WT CRC patients (Figure 6C), indicating that a selection
for expression of one versus the other receptor had not taken
place in CRC. Strikingly, however, low expression of TRAIL-R2,
but not TRAIL-R1, correlated with prolonged metastasis-free
survival of patients with KRAS mutant CRC (Figure 6D) but notCancer Cell 27, 561–573, April 13, 2015 ª2015 Elsevier Inc. 567
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Figure 4. TRAIL-R2 Promotes Activation of a Promigratory Rac1/PI3K Signaling Axis
(A) A549-luc pLKO.1 and shTRAIL-R2 cells were fixed and stained using Texas red-coupled phalloidin and DAPI. Representative confocal images are shown;
scale bar represents 25 mm.
(B) A549-luc pLKO.1 and shTRAIL-R2 were subjected to pulldown of GTP-bound Rac1 using PAK1 beads and western blotting.
(C) A549-luc cells were transfected as shown and subjected to migration assays.
(D) A549-luc cells were transfected with GFP, Rac1, or dnRac1 (Rac1T17N) and subjected to immunoprecipitation via addition of Flag-tagged TRAIL after lysis
and western blot analysis. Asterisks indicate the immunoprecipitation (IP) antibody heavy chain.
(E) Endogenous Rac1 in A549-luc cell lysates was loaded with GDP/GTPgS in vitro, and GTP-bound Rac1 was isolated using PAK1-RBD beads and analyzed by
western blot.
(legend continued on next page)
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Figure 5. mTRAIL-R and mTRAIL Promote
Rac1 Activity in KPC Tumors In Vivo
(A) Intravital imaging was performed on mice
bearing either KPC-pLKO (n = 3) or -shmTRAIL-R
(23, 25, n = 3 each) tumors, and average lifetime
fluorescence was quantified. Representative
western blots are shown.
(B) Lifetime maps of representative single KPC-
pLKO.1 or -shmTRAIL-R (sh25) cells in vivo. SHG,
second harmonic generation. Scale bar repre-
sents 50 mm.
(C) Intravital imaging was performed on mice
bearing KPC tumors before and 1 hr after treat-
ment with either vehicle or mTRAIL-R-Fc. Average
lifetime fluorescence was quantified.
(D) Parental KPC cells were transiently transfected
with a Rac-FRET reporter and treated with
mTRAIL-R-Fc for the indicated times in vitro.
Single cells were analyzed as in (A).
Values are means ± SEM of three independent
experiments. ns, not significant, *p < 0.05, **p <
0.01 and ***p < 0.0001 (Mann-Whitney test); [ns],
nano seconds. See also Figure S4.in patients with WT KRAS CRC (Figure 6E). Together, these data
support a proinvasive and prometastatic role of TRAIL-R2 in
KRAS-mutated human cancers.
DISCUSSION
Treatment with recombinant TRAIL was selectively able to kill
tumor cells in vivo without toxicity (Ashkenazi et al., 1999; Walc-
zak et al., 1999). It is therefore counterintuitive that apoptosis-
inducing TRAIL-Rs are highly expressed in many cancers
(Daniels et al., 2005; Elrod et al., 2010; Ganten et al., 2009;
Macher-Goeppinger et al., 2009; Ozawa et al., 2001; Sanlioglu
et al., 2007; Spierings et al., 2003).
We show here that cancer cell-expressed mTRAIL-R pro-
motes cancer progression, invasion, and metastasis in KRAS-
driven autochthonous mouse models of NSCLC and PDAC.
Constitutive signaling from TRAIL-R2 promotes activation of a
Rac1/PI3K signaling axis that increases migration and invasion
in a cancer cell-autonomous manner. Moreover, we provide
in vivo evidence that endogenous mTRAIL and mTRAIL-R
activate Rac1 in KPC tumor cells. Interestingly, Rac1 has(F) The indicated cell lines were subjected to KDs or NSC23766 treatment (100 mM) for 72 hr and then BrdU
(G) A549-luc cells were subjected to the indicated KDs and migration assays or western blot analysis in the
(H) FADD-deficient and proficient A549-luc cells were transfected with TRAIL-R2-targeting siRNAs and A54
DICD or DDD/CTD. All cells were subjected to western blotting.
(I) A549-luc, PancTu-I, and DLD-1 cells were transfected as indicated and subjected to migration assays or
(J) Proposed model of migration signaling mediated by endogenous TRAIL/TRAIL-R2 in KRAS-mutated cell
Representative western blots are shown. Values are means ± SEM of three independent experiments. ICD,
Control; TR2, TRAIL-R2; *p < 0.05, **p < 0.01, and ***p < 0.0001 (ANOVA). See also Figure S3.
Cancer Cell 27, 561–5been shown to be required for early
metaplastic changes in autochthonous
KRAS-driven NSCLC (Kissil et al., 2007)
and PanIN formation (Heid et al., 2011)
in linewith our finding that mTRAIL-R pro-
motes Rac1 activity in both cancers.Moreover, elevated Rac1 activity has been measured in KPC tu-
mors as compared with normal pancreatic tissue (Johnsson
et al., 2014). Our results now show that blocking the endogenous
TRAIL/mTRAIL-R interaction reduces Rac1 activation, delays tu-
mor growth, and blunts metastasis. Since TRAIL- and TRAIL-R-
deficient mice do not show a gross phenotype (Cretney et al.,
2002; Finnberg et al., 2008; Grosse-Wilde et al., 2008), therapeu-
tic inhibition of TRAIL or TRAIL-R2 is unlikely to cause toxicity
and might therefore be advantageous over other therapeutic
strategies targeting KRAS-effector pathways.
Mechanistically, we identify that TRAIL-R2mediates migration
via the MPD of TRAIL-R2. Intriguingly, human TRAIL-R2 and
mTRAIL-R share a part of the MPD that is not present in the
TRAIL-R1 MPD. It will therefore be interesting to delineate the
precise molecular pathway that is triggered from this domain.
This will, however, require more sensitive experimental ap-
proaches, as the endogenous TRAIL/TRAIL-R complex is not
abundant enough for proteomic analysis (data not shown).
Recently, endogenous TRAIL-R2 has been shown to promote
proliferation of pancreatic cancer cell lines via inhibition of let-7
maturation in the nucleus in a ligand-independent mannerproliferation assays.
presence or absence of GDC-0941 (1 mM).
9 shTRAIL-R2 cells were reconstituted with either
western blot analysis.
s.
intracellular domain; CTD, C-terminal domain; Ctr,
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Figure 6. High TRAIL-R2 Expression Correlates with Markers of Malignancy in Patients with KRAS-Mutated Cancers
(A) TRAIL-R1 and TRAIL-R2 expression in human PDAC samples of 95 patients was quantified. More than 20% of positive (intensity of a minimum of 1 on a scale
of 1 to 3; Ganten et al., 2009) cancer cells within one patient sample were considered high expression and included into the figure, which depicts percentage of
high TRAIL-R expression within the patient population. Representative stainings from two patients are shown. Scale bar represents 25 mm. Fisher’s exact test
***p < 0.0001.
(B) TRAIL-R2 expression was determined in a human PDAC cohort (n = 106). All tumors were positive ranging from score 3 to 7 (median = 5). Data were
dichotomized by the median 5, and the percentage of cases above (black) and below (white) median was calculated separately for cases with lymph vessel
invasion (L1, n = 71) and cases without lymph vessel invasion (L0, n = 30). In five patients, lymph vessel invasion had not been determined, although tumors also
stained positive. Fisher’s exact test **p = 0.001.
(C) TRAIL-R1 and TRAIL-R2 expression levels (H score) in lung metastases of KRAS-mutated and KRAS-WT CRC. The central line represents the mean. Error
bars are ± SEM.
(D) Metastasis-free (Kaplan-Meier) survival according to high or low TRAIL-R1/2 expression (i.e., above or below respective H-score median) in patients with
KRAS-mutated CRC. Log-rank test, ns = not significant; *p < 0.02.
(E) As in (D), in patients with KRAS-WT CRC. Log-rank test, ns = not significant; *p < 0.02.(Haselmann et al., 2014). We find endogenous TRAIL bound to
TRAIL-R2 associated with the active form of Rac1, which is
mainly found in association with the plasma membrane, sug-
gesting that the TRAIL/TRAIL-R2-mediated Rac1 activation oc-
curs at the plasma membrane.570 Cancer Cell 27, 561–573, April 13, 2015 ª2015 Elsevier Inc.Wepreviously showed in an autochthonousmodel of skin can-
cer formation, driven by oncogenic mutation of Hras (Balmain
et al., 1984), that constitutive mTRAIL-R deficiency suppressed
metastasis (Grosse-Wilde et al., 2008). This antimetastatic role
of the mTRAIL-R seems to contradict the findings reported
here. However, we could confirm an antimetastatic role for
TRAIL-R1 in patients with KRAS-WT CRC as high expression
of this receptor correlated with prolonged metastasis-free
survival. In contrast to this, high TRAIL-R2 expression in
KRAS-mutated CRC correlated with shortened metastasis-free
survival, suggesting that the role of TRAIL-R2 and TRAIL-R1 as
well as mTRAIL-R is dependent on the oncogenic context.
Accordingly, TRAIL-R2 suppression does not affect migration
in KRAS-WT or HRAS-mutated cells (data not shown). Further-
more, we identify ROCK inhibition to be the prerequisite for
TRAIL/TRAIL-R2-mediated migration. In addition, induction of
oncogenic HRAS expression, which did not allow for TRAIL-
R2-mediated migration, also did not inhibit ROCK activity (data
not shown). It will therefore be interesting to investigate whether
other pathways that inhibit ROCK might utilize TRAIL/TRAIL-R2
similarly.
In conclusion, we identify cancer cell endogenous TRAIL-R2/
mTRAIL-R stimulation as a promoter of cancer progression, in-
vasion, and metastasis of KRAS-mutated cancers offering an
explanation as to why these cancers not only retain TRAIL-R
expression but also frequently upregulate it. On the basis of
these results, it is tempting to speculate whether patients with
KRAS-mutated cancers that are resistant to apoptosis induction
might benefit from inhibition of the constitutive TRAIL/TRAIL-R2
interaction.
EXPERIMENTAL PROCEDURES
Animal Models
A549 Lung Tumors
Twelve-week-old female Fox Chase SCID Beige mice (Charles River) were in-
jected with 23 106 A549-luc vector control or shTRAIL-R2 cells via the lateral
tail vein. Starting on day 1 after cell injection, all mice were imaged weekly for
bioluminescence using the IVIS Spectrum at 1-min exposure time (Caliper Life
Science). Photons per second (Photon Flux) were quantified using IVIS Spec-
trum software.
Orthotopic PDAC Metastasis
Experiments were carried out in female SCID beige mice (Charles River). 1 3
106 PancTu-I shCtr or shTRAIL-R2 were orthotopically transplanted into the
pancreas, and tumors were resected 10 days later as previously described
(Egberts et al., 2008). Animals were sacrificed and organs preserved at day
26 postresection.
K(P)C-mTRAIL-R Mice
Mixed-gender KrasG12D, p53R172H, and PDX-1-Cre mice on C57BL/6 back-
ground were kindly provided by D. Tuveson, and mTRAIL-RFL/FL mice on
C57BL/6 background were previously generated by our laboratory (Grosse-
Wilde et al., 2008).
KP-mTRAIL-R Mice
Mixed-gender KrasG12D;p53R172H;mTRAIL-RWT/WT or FL/FL mice were intrana-
sally infected with a single dose of 2 3 107 pfu Ad-Cre to induce tumors.
Rac-FRET Tumors
After transfection of KPC shCtr and shTRAIL-R2 cell lines with a GFP and RFP
version of the Rac-FRET reporter (Mack et al., 2012) and selection for stable
expression with neomycin, 2 3 106 cells were subcutaneously injected
into the flanks of nude mice. Following primary tumor development of 7 to
8 days, a cutaneous version of the abdominal imaging window described pre-
viously (Ritsma et al., 2013) was surgically implanted on top of the tumors un-
der isoflurane. Mice were subsequently imaged for up to 2 hr on a 37C heated
stage under isoflurane, using the described multiphoton TCSPC system.
For treatment with mTRAIL-R-Fc, mice were imaged prior to and 1 hr after
intraperitoneal injection of either PBS or 0.5 mg per mouse of mTRAIL-R-Fc.
The orthotopic PDACmetastasis experiment was conducted in accordance
with the Office of Laboratory Animal Welfare and the German Federal Animal
Protection Laws and approved by the Institutional Animal Care and Use Com-mittees of the University of Kiel. The Rac-FRET experiments were conducted
under an appropriate animal project license approved by the UK home office
and in accordance with the Animal Welfare and Experimental Ethics Commit-
tee at the Beatson Institute of Cancer Research. All other animal experiments
were conducted under an appropriate animal project license approved by the
UK home office, in accordance with the revised (2013) Animals (Scientific Pro-
cedures) Act (ASPA) and the institutional guidelines of the UCL Cancer
Institute.
siRNA-Mediated KD
KD experimentswere performed by transient transfection of siRNA smartpools
or single siRNA sequences to silence the indicated proteins or RISC-free con-
trol using Dharmafect I (Dharmacon) following the instruction manual. All cell
lines were incubated for 48 hr to achieve sufficient KD efficiency. See Supple-
mental Experimental Procedures for detailed description.
Migration/Invasion Assays
Migration/Invasion assays were performed using the xCELLigence System
(Cambridge Bioscience). See Supplemental Experimental Procedures for
detailed description.
Patient Cohorts
Informed consent was obtained from all individuals, and use of samples for his-
tology was approved by the ethics committees of the University of Heidelberg
(PDAC cohort 1), Kiel (PDAC cohort 2), and of the Medical University of Vienna
(CRC lungmetastasis cohort). See Supplemental Experimental Procedures for
detailed description.
Statistical Analysis
Data were analyzed using GraphPad Prism 5 software (GraphPad Software).
Results are expressed as means ± SEM. Statistical significance between
groups was determined using Student’s t test and/or one-way ANOVA, fol-
lowed by the Bonferroni post-test. A p value of < 0.05 was considered signif-
icant: **p < 0.01 and ***p < 0.001 (ns = nonsignificant).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.ccell.2015.02.014.
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